145781-92-6

Goserelin acetate, like leuprolide acetate, is a synthetic superagonist nonapeptide analogue of GnRH that possesses greater potency than the natural hormone. Note that it contains D-Ser(But) and NH-NHCONH2 in place of Gly6 and Gly10-NH2, respectively. That is, the C terminal modification simply has an NH substituting for the CH2 of Gly, and like the C-terminal change in leuprolide acetate, this inhibits enzymatic degradation of the peptide by the postproline carboxyamide peptidase.
Goserelin acetate is available in the form of a small, solid pellet that is administered as an SC implant for the palliative treatment of advanced, metastatic breast cancer in pre- and perimenopausal women or, similarly, as a palliative in advanced prostatic cancer. The rationale for this drug's use is, as described above, its ability as a superagonist to bring the levels of estradiol or testosterone to near castrate levels, thus slowing the progression of breast or prostate carcinoma, respectively. Additionally, goserelin acetate is approved for use in treating endometriosis for up to 6 months.

White Solid

Anticancer

injectable gonadotropin releasing hormone superagonist (GnRH agonist) or luteinizing hormone antiproliferative activity in breast, prostate and endometrial cancers

Synthetic peptide agonist analog of LH-RH. Antineoplastic (hormonal).

Goserelin acetate peptide results in significant inhibition of gonadotropin release and suppresses steroidogenesis in ovaries and testis. Thus, it leads to a reduction of testosterone to castration levels and estrogen to postmenopausal levels. Therefore, this peptide is used for reducing testosterone levels in patients with locally advanced prostate cancer.

Goserelin acetate also is used in combination with the antiandrogen flutamide for shrinking prostate carcinoma before radiation therapy. This maximal androgen blockade combination is used when the prostate carcinoma has been staged as locally confined to the prostate gland, with one or both lobes as well as the seminal vesicles involved. The treatment should start 8 weeks before radiation treatment begins and be continued throughout the radiation therapy.
Furthermore, women who are to undergo hysterectomy for menorrhagia can benefit from previous treatment with goserelin acetate, because it is able to induce endometrial thinning. This thinning of the endometrium improves the operating environment by causing less intrauterine bleeding, increased postoperative amenorrhea, and decreased dysmenorrhea following surgery, which is why goserelin acetate is approved for inducing endometrial thinning prior to a patient undergoing a hysterectomy for heavy menstrual bleeding.

Store at -20°C

[1] INDIRA NEDERPELT. Characterization of 12 GnRH peptide agonists – a kinetic perspective[J]. British Journal of Pharmacology, 2015, 173 1: 128-141. DOI: 10.1111/bph.13342
[2] E CHATZAKI. The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor.[J]. Cancer research, 1996, 56 9: 2059-2065.
[3] M H SULLIVAN  B A C. The role of calcium in luteinizing hormone-releasing hormone agonist (ICI 118630)-stimulated steroidogenesis in rat Leydig cells.[J]. Biochemical Journal, 1984, 218 2: 621-624. DOI: 10.1042/bj2180621
[4] JERRY A. WARD. Prolonged Suppression of Rat Testis Function by a Depot Formulation of Zoladex,? a GnRH Agonist[J]. Journal of andrology, 1989, 10 6: 478-486. DOI: 10.1002/j.1939-4640.1989.tb00144.x
[5] DONATELLA DONDI. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice[J]. International Journal of Cancer, 1998, 76 4: 506-511. DOI: 10.1002/(sici)1097-0215(19980518)76:4<506::aid-ijc11>3.0.co;2-5